OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC

January 12th 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

Dr. Dhakal on the Implementation of Trastuzumab Deruxtecan Across the HER2+ Breast Cancer Landscape

January 12th 2023

Ajay Dhakal, MBBS, discusses the evolution and implementation of the antibody-drug conjugate trastuzumab deruxtecan across the landscape of HER2-positive breast cancer landscape.

Dr. Mercado on Evolution of Biopsy Techniques in Lung Cancer

January 12th 2023

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Dr. O’Regan on the SOFT Trial in Premenopausal Women With HR+ Breast Cancer

January 12th 2023

Ruth M. O’Regan, MD, discusses the significance of the Breast Cancer Index as a prognostic tool, as well as the investigation of the phase 3 SOFT trial for patients with early-stage, hormone receptor-positive breast cancer.

Dr. Mayer on the PACE Trial in HR+/HER2– Breast Cancer

January 12th 2023

Erica L. Mayer, MD, MPH, discusses findings from the phase 2 PACE trial in patients with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer.

Dr. Jimenez on the Management of Radiation Toxicities in Breast Cancer

January 12th 2023

Rachel Jimenez, MD, discusses the management of toxicities associated with radiotherapy for patients with breast cancer.

Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast Cancer

January 12th 2023

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.

Dr. Wu on the Current Utility of Targeted Therapy in CRC

January 12th 2023

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

January 12th 2023

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCC

January 12th 2023

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC

January 10th 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

January 10th 2023

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Dr. Ahluwalia on the Evaluation of SurVaxM With Temozolomide in Newly Diagnosed Glioblastoma

January 10th 2023

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

Dr. Force on the Efficacy of Trastuzumab Deruxtecan in the DESTINY-Breast02 Trial for HER2+ Breast Cancer

January 9th 2023

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Dr. Patel on the Sequencing of Immunotherapy and Targeted Therapy in BRAF-Mutant Melanoma

January 9th 2023

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Dr. Bartsch on the Real-World Evaluation of the ELEANOR Study in HR+/HER2-Overexpressed Breast Cancer

January 6th 2023

Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

January 6th 2023

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Dr. Contreras on the Role of Neoadjuvant Pembrolizumab in Desmoplastic Melanoma

January 6th 2023

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

Dr. Aragon-Ching on the Use of Maintenance Avelumab in Urothelial Carcinoma

January 6th 2023

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

Dr. Lustberg on the Real-World Use of Ovarian Suppression in HR+/HER2+ Breast Cancer

January 5th 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.